Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Blueprint Medicines Corp is a biotechnology business based in the US. Blueprint Medicines shares (BPMC) are listed on the NASDAQ and all prices are listed in US Dollars. Blueprint Medicines employs 580 staff and has a trailing 12-month revenue of around $230.5 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $66.34 |
|---|---|
| 52-week range | $43.46 - $117.86 |
| 50-day moving average | $65.90 |
| 200-day moving average | $68.18 |
| Wall St. target price | $90.53 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-11.06 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $66.34 from 2022-09-27
| 1 week (2022-09-21) | -2.57% |
|---|---|
| 1 month (2022-08-26) | -8.15% |
| 3 months (2022-06-28) | 24.09% |
| 6 months (2022-03-28) | 1.42% |
| 1 year (2021-09-28) | -36.09% |
|---|---|
| 2 years (2020-09-28) | -25.36% |
| 3 years (2019-09-27) | 73.19 |
| 5 years (2017-09-28) | 68.45 |
| Revenue TTM | $230.5 million |
|---|---|
| Gross profit TTM | $-446,688,000 |
| Return on assets TTM | -31.54% |
| Return on equity TTM | -67.58% |
| Profit margin | 0% |
| Book value | $12.53 |
| Market capitalisation | $3.9 billion |
TTM: trailing 12 months
We're not expecting Blueprint Medicines to pay a dividend over the next 12 months.
Over the last 12 months, Blueprint Medicines's shares have ranged in value from as little as $43.46 up to $117.86. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Blueprint Medicines's is 0.7743. This would suggest that Blueprint Medicines's shares are less volatile than average (for this exchange).
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc. ; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc. ; F.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.